Hims & Hers said Saturday it will pull its compounded semaglutide weight-loss pill after backlash and threats of legal action.

The telehealth company said it decided to stop offering the treatment following discussions with industry stakeholders, while emphasizing its commitment to safe and affordable care.

The pill was intended as a cheaper alternative to Novo Nordisk’s Wegovy, priced as low as $49 for the first month.

Novo Nordisk accused Hims of illegal mass compounding, and the FDA announced plans to pursue legal action, including possible referrals to the Justice Department, CNBC has reported.

The decision comes just ahead of Hims & Hers’ Super Bowl ad addressing the link between wealth inequality and health access.